Myocarditis
For the WikiPatient page for this topic, click here
Editors-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Homa Najafi, M.D.[2]Varun Kumar, M.B.B.S.; Cafer Zorkun, M.D., Ph.D. [3]; Maliha Shakil, M.D. [4]
Synonyms and keywords: Inflammatory cardiomyopathy; Idiopathic myocarditis; Viral cardiomyopathy; inflammation of the heart muscle; myocardium inflammation; bacterial myocarditis; viral myocarditis; fungal myocarditis; spirochaetal myocarditis; protozoal myocarditis; parasitic myocarditis; rickettsial myocarditis; autoimmune myocarditis; immune-mediated myocarditis; allergen-mediated myocarditis; alloantigen-mediated myocarditis; autoantigen-mediated myocarditis; toxic myocarditis; dug-mediated myocarditis; drug-related myocarditis; acute myocarditis; chronic myocarditis; sarcoidosis-related myocarditis; giant cell myocarditis; autoreactive myocarditis; healed myocarditis; pediatric myocarditis; myocarditis in children; children myocarditis; pediatric inflammatory cardiomyopathy; pediatric inflammation of heart muscle; Inflammatory cardiomyopathy in children; inflammation of the heart muscle in children; Postviral autoimmune-related myocarditis; Infectious myocarditis; hypersensitivity myocarditis; fulminant myocarditis, eosinophilic myocarditis
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Varun Kumar, M.B.B.S. Maliha Shakil, M.D. [2] Homa Najafi, M.D.[3]
Overview
Myocarditis is defined as inflammation of the myocardium. It may present with chest pain, ST segment elevation, elevated biomarkers of myonecrosis, heart failure, and/ or sudden death. Myocarditis can be classified clinicopathologically into fulminant myocarditis, acute myocarditis, chronic active myocarditis, and chronic persistent myocarditis. During either an infection or a hypersensitivity reaction, the inflammatory response may cause myonecrosis either directly or indirectly as part of an autoimmune reaction. Life-threatening causes of myocarditis include carbon monoxide poisoning and Dengue fever. Common causes of myocarditis include infections, Lyme disease, and medications. Idiopathic myocarditis is the most common type of myocarditis and is often suspected to be secondary to a viral infection. Myocarditis must be distinguished from pericarditis and the life threatening condition of ST elevation myocardial infarction. In young adults, up to 20% of all cases of sudden death are due to myocarditis. Myocarditis is slightly more frequent among males than females. Myocarditis is usually self limiting and is associated with a good prognosis especially if it is secondary to a viral infection. Patients rarely develop cardiac failure, pulmonary edema, arrhythmias, or cardiogenic shock. In some instances, myocarditis may be associated with sudden death. Patients with fulminant myocarditis have a good long term prognosis if they survive the acute phase of the disease. The prognosis of fulminant myocarditis is better than that of either acute myocarditis or giant cell myocarditis. The presence of left bundle branch block, q waves, AV block, syncope and a left ventricular ejection fraction < 40% are associated with sudden death and cardiac transplantation. The physical examination in patients with myocarditis may reveal tachycardia, a cardiac gallop, mitral regurgitation due to left ventricular dilation, and pedal edema suggestive of cardiac failure. A pericardial friction rub may be noted in presence of concomitant pericarditis, a condition sometimes referred to as myopericarditis.
Historical Perspective
Myocarditis was first discovered by Jean Baptiste Senac, a French physician, in 1794. The term myocarditis was introduced by German physician Joseph Friedrich Sobernheim in 1837. In 1980s, the World Health Organization and the International Society and Federation of Cardiology were the first to differentiate between myocarditis and other cardiomyopathies. The Dallas criteria was published in 1986 as a guideline for classification of myocarditis.
Classification
Myocarditis can be classified based on the causative, histological, and clinicopathological criteria. Causative criteria include three main groups, as well as infectious, immune-mediated, and toxic myocarditis. Based on the type of infiltrating cells myocarditis divided in lymphocytic, eosinophilic, polymorphic, giant cell myocarditis, and cardiac sarcoidosis. Acute, fulminant, chronic active, and chronic persistent are subtypes of clinicopathopogical classification.
Pathophysiology
During either an infection or a hypersensitivity reaction, the inflammatory response may cause myonecrosis either directly or indirectly as part of an autoimmune reaction.
Causes
Life-threatening causes of myocarditis include carbon monoxide poisoning and Dengue fever. Common causes of myocarditis include infections such as Lyme disease and medications. Idiopathic myocarditis is the most common type of myocarditis and is often suspected to be secondary to a viral infection.
Differentiating Myocarditis from other Diseases
Myocarditis must be distinguished from pericarditis and the life threatening condition of ST elevation myocardial infarction.
Risk factors
There are no established risk factors for myocarditis.
Screening
There is insufficient evidence to recommend routine screening for myocarditis.
Epidemiology and Demographics
The incidence of myocarditis is approximately 10 to 20 per 100,000 patients worldwide. It commonly affects younger individuals. Yong males are slightly more commonly affected by myocarditis than females. There is no racial predilection to myocarditis. Viral infections especially coxsackie B and enterovirus are the most common cause of myocarditis in developed countries. While, In South America, Chagas’ disease (caused by Trypanosoma cruzi) is the main cause of myocarditis.
Natural History, Complications and Prognosis
Myocarditis is usually self limiting and is associated with a good prognosis especially if it is secondary to a viral infection. Patients rarely develop cardiac failure, pulmonary edema, arrhythmias, or cardiogenic shock. In some instances, myocarditis may be associated with sudden death. Patients with fulminant myocarditis have a good long term prognosis if they survive the acute phase of the disease. The prognosis of fulminant myocarditis is better than that of either acute myocarditis or giant cell myocarditis. The presence of syncope, pulmonary hypertension, biventricular dysfunction, left bundle branch block, q waves, AV block, and a left ventricular ejection fraction < 40% are associated with sudden death and cardiac transplantation. Complications of myocarditis include chronic dilated cardiomyopathy, heart block, congestive heart failure, pericarditis, ventricular dysfunction, arrythmias, and sudden cardiac death.
Diagnosis
History and Symptoms
Myocarditis should be suspected in a patient with acute decompensation of cardiac function who is at low risk of ischemic heart disease. A history of a recent (within the preceding 2-4 weeks) viral illness is often elicited in a large number of patients with myocarditis. Cardiac specific symptoms may become apparent usually in the subacute virus-clearing phase. In myocarditis due to drug hypersensitivity, patients may give a history of ingesting an offending drug. In fulminant myocarditis, patients present with the abrupt onset of flu-like symptoms and the abrupt onset of heart failure symptoms. In chronic and acute myocarditis, the onset of symptoms may be more insidious. Common symptoms of myocarditis include chest pain, pedal edema, palpitations, fever, and joint pains.
Physical Examination
There are no specific findings for myocarditis. Patients with myocarditis usually show signs of cardiac dysfunction and underlying diseases. The physical examination in patients with myocarditis may reveal tachycardia, a cardiac gallop, mitral regurgitation due to left ventricular dilation, and pedal edema suggestive of cardiac failure. A pericardial friction rub may be noted in presence of concomitant pericarditis, a condition sometimes referred to as myopericarditis.
Laboratory Findings
Laboratory findings consistent with the diagnosis of myocarditis include elevated markers of myonecrosis, inflammatory markers, and other biomarkers. Markers of myonecrosis include creatine kinase (CK-MB), cardiac troponin I (cTnI) or T (cTnT), lactate dehydrogenase (LDH), alanine transaminase (ALT), and aspartate transaminase (AST). Elevated levels of C-reactive protein and erythrocyte sedimentation rate (ESR), and leukocytosis are suggestive of myocarditis. Serologic markers such as Fas, Fas ligand, interleukin-10 or antimyosin autoantibodies are of prognostic value in myocarditis. Other auto-antibodies such as ANA and rheumatoid factor may also be detected.
Electrocardiogram
The presence of ST segment elevation in patients with myocarditis can mimic pericarditis and myocardial infarction. Arrhythmias and heart block may also be observed in myocarditis patients. Myocarditis can be distinguished from pericarditis by the presence of PR depression in the patient with pericarditis.
Endomyocardial Biopsy
Endomyocardial biopsy remains the gold standard test to evaluate for the presence of and to subclassify the type of myocarditis. A small tissue sample of the endocardium and myocardium is obtained via right sided cardiac catheterization. The sample is then evaluated by a pathologist using immunochemistry and special staining techniques as necessary. Histopathological features include abundant edema in the myocardial interstitium and an inflammatory infiltrate which is rich in lymphocytes and macrophages. Focal destruction of myocytes as a result of the inflammatory process results in left ventricular dysfunction. Endomyocardial biopsy is recommended when the results would identify an underlying disease that is amenable to therapy. Routine performance of endomyocardial biopsy is not recommended in all patients with myocarditis.
Chest X Ray
Findings on chest x-ray suggestive of myocarditis include cardiomegaly, cephalization of the pulmonary vessels and, Kerley B-lines in presence of heart failure pericardial thickening in presence of pericarditis, pulmonary edema, and pleural effusion.
Echocardiography
Echocardiography in patients with myocarditis allows for serial assessment of left ventricular dysfunction and can be used to distinguish fulminant (non-dilated hypocontractile left ventricle with thick interventricular septum) from acute myocarditis (dilated hypocontractile left ventricle with normal interventricular septum). Echocardiography may be helpful in the diagnosis of myocarditis. Findings on an echocardiography suggestive of myocarditis include wall motion abnormalities, systolic and diastolic dysfunction, changes in image texture, pericardial effusion, and functional regurgitation through the AV valves.
CT scan
Cardiac CT scan may be helpful in the diagnosis of myocarditis. Cardiac CT scan can be used in diagnosis of acute myocarditis ( subepicardial late iodine enhancement), exclusion of acute coronary syndrome by CT angiography, and alternative diagnostic tool in patients with CMR contraindications.
MRI
Cardiac MRI is indicated in patients with new or persisting symptoms of chest pain and congestive heart failure, who have evidence of significant myocardial injury, in the absence of or in whom there is a low suspicion of coronary atherosclerosis. Cardiac MRI findings associated with myocarditis include myocardial inflammation, myocardial edema, capillary leak, and reduced left ventricular function. While the CMR pattern of gadolinium hyperenhancement in ST segment elevation myocardial infarction is transmural and extends from the endocardium to the epicardium, the patchy, non-segmental hyperenhancement pattern in myocarditis in contrast involves the epicardium and spares the subendocardium. CMR has a sensitivity of 76%, specificity of 95.5%, and overall diagnostic accuracy of 85% when any-two of the following three sequences are used, focal and global T2 signal intensity, myocardial global relative enhancement, and delayed gadolinium enhancement.
Other Imaging Findings
Coronary angiography may be helpful in excluding either myocardial ischemia or infarction as the cause of ST segment elevation, elevated cardiac biomarkers, or left ventricular dysfunction. Nuclear imaging may be useful in diagnosis of cardiac sarcoidosis.
Other Diagnostic Findings
Treatment
Medical Therapy
Symptomatic treatment is the mainstay of therapy for patients with viral myocarditis. Supportive therapy includes diuretics and inotropes for left ventricular failure. ACE inhibitor therapy may aid in left ventricular remodeling. Among patients with fulminant myocarditis, placement of either an intra-aortic balloon pump or a left ventricular assist device may be necessary as bridge to recovery. Administration of antimicrobial therapy is recommended for bacterial myocarditis. Immunosuppressive therapy may be effective in the management of giant cell myocarditis, autoimmune myocarditis, and eosinophilic myocarditis. In patients with arrythmias, treatment should be initiated only if arrhythmias are symptomatic or sustained. Myocarditis patients presenting with conduction abnormalities, particularly Mobitz type II and complete heart block require temporary pacemaker usually during the acute phase.
Surgery
Cardiac transplantation is sometimes required to treat refractory giant cell myocarditis. However, the condition can recur in post-transplant patients.
Primary prevention
There are no established measures for the primary prevention of all types of myocarditis. Vaccination against measles, rubella, mumps, poliomyelitis, and influenza could prevent myocarditis secondary to these diseases.
Secondary prevention
Effective measures for the secondary prevention of myocarditis include, clinical evaluation, ECG, and echocardiography. CMR, cardiac CT scan, nuclear assessment in patients that echocardiography is undiagnostic. Patients should udergo cardiac function assessment at one and six months and yearly after that.
References
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maliha Shakil, M.D. [2]
Overview
Cases of myocarditis have been documented as early as the 1600’s. The term myocarditis was introduced by German physician Joseph Friedrich Sobernheim in 1837.[1] The Dallas criteria was published in 1986 as a guideline for classification of myocarditis.[2]
Historical Perspective
- Cases of myocarditis have been documented as early as the 1600’s.[1]
- The term myocarditis was introduced by German physician Joseph Friedrich Sobernheim in 1837.[1]
- The Dallas criteria was published in 1986 as a guideline for classification of myocarditis.[2]
References
- ↑ 1.0 1.1 1.2 Myocarditis. Wikipedia. https://en.wikipedia.org/wiki/Myocarditis Accessed on September 30, 2015
- ↑ 2.0 2.1 Magnani JW, Dec GW (2006). “Myocarditis: current trends in diagnosis and treatment”. Circulation. 113 (6): 876–90. doi:10.1161/CIRCULATIONAHA.105.584532. PMID 16476862. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help)
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Varun Kumar, M.B.B.S. Maliha Shakil, M.D. [2] Homa Najafi, M.D.[3]
Overview
Myocarditis can be classified based on the causative, histological, and clinicopathological criteria. Causative criteria include three main groups, as well as infectious, immune-mediated, and toxic myocarditis. Based on the type of infiltrating cells myocarditis divided in lymphocytic, eosinophilic, polymorphic, giant cell myocarditis, and cardiac sarcoidosis. Acute, fulminant, chronic active, and chronic persistent are subtypes of clinicopathopogical classification.
Classification
- Myocarditis can be classified based on the causative, histological, and clinicopathological criteria.
- Myocarditis may be classified according to causative criteria into three groups:[1][2][3][4][5][6][7][8][9]
- Infectious myocarditis
- Immune-mediated myocarditis
- Toxic myocarditis
- Myocarditis may be classified according to histological criteria into five groups:[10][11][2]
- Lymphatic myocarditis
- Eosinophilic myocarditis
- Polymorphic myocarditis
- Giant cell myocarditis
- Cardiac sarcoidosis
- Myocarditis may be classified according to clinicopathological four criteria into three groups:[12][13][14]
Causative criteria
- Myocarditis can be classified based on the causative criteria into immune-mediated myocarditis, infectious myocarditis and toxic myocarditis. bkjvskaljbkjbkjbakj
| Immune-mediated myocarditis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Allergens | Alloantigens | Autoantigens | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| •Tetanus toxoid
•Vaccines •Serum sickness | Drugs:
•Penicillin •Cefaclor •Colchicine •Furosemide •Isoniazid •Lidocaine •Tetracycline •Sulfonamides •Phenytoin •Phenylbutazone •Methyldopa •Thiazide diuretics •Amitriptyline | Heart transplant rejection | •Infection-negative lymphocytic
| Autoimmune disorders:
•SLE •Rheumatoid arthritis •Churg-Strauss syndrome •Kawasaki’s disease •IBD •Scleroderma •Polymyositis •Myasthenia gravis •DM type1 •Thyrotoxicosis •Sarcoidosis •Wegener’s granulomatosis •Rheumatic heart disease | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Toxic myocarditis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drugs | Heavy metals | Hormones | Physical agents | Miscellaneous | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| •Amphetamines
•Anthracyclines •Cocaine •Cyclophosphamide •Ethanol •Fluorouracil •Lithium •Catecholamines •Hematine •Interleukin-2 •Trastuzumab •Clozapine | •Copper
•Iron •Lead | •Phaeochromocytoma
| •Radiation
| •Scorpion sting
•Snake, and spider bites •Bee and wasp stings •Carbon monoxide •Inhalant •Phosphorus •Arsenic •Sodium azide | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Infectious myocarditis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Bacterial | Spirochaetal | Fungal | Protozoal | Parasitic | Rickettsial | Viral | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| •Staphylococcus
•Streptococcus •Pneumococcus •Meningococcus •Gonococcus •Salmonella •Corynebacterium diphtheriae •Haemophilus influenzae •Mycobacterium tuberculosis •Mycoplasma pneumonia •Brucella | •Borrelia •Leptospira | •Aspergillus
•Actinomyces •Blastomyces •Candida •Coccidioides •Cryptococcus •Histoplasma •Mucormycosis •Nocardia •Sporothrix | •Trypanosoma cruzi
•Toxoplasma gondii •Entamoeba •Leishmania | •Trichinella spiralis
•Echinococcus granulosus •Taenia solium | •Coxiella burnetii
•R.rickettsii •R.tsutsugamushi | •Coxsackievirus
•Echoviruses •Polioviruses •Influenza A & B viruses •RSV •Mumps virus •Measles virus •Rubella virus •Hepatitis C virus •Dengue virus •Yellow fever virus •HIV-1 •Adenoviruses •Paravirus B19 •Cytomegalovirus •HSV-6 •EBV •VZV •HSV | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Histological criteria
- Myocarditis can be classified based on the type of infiltrating cells in lymphocytic, eosinophilic, polymorphic, giant cell myocarditis, and cardiac sarcoidosis.
| Classification based on histological criteria | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lymphocytic | Eosinophilic | Polymorphic | Giant cell | Cardiac sarcoidosis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinicopathological criteria
- Fulminant myocarditis: Fulminant myocarditis occurs following a viral prodrome. Fulminant myocarditis presents as acute severe cardiovascular compromise with ventricular dysfunction. On endomyocardial biopsy, there are multiple foci of inflammation.[15][16]
- Acute myocarditis: Acute myocarditis presents with a less distinct onset of the illness. When the patient does present, there is already a decline in left ventricular dysfunction. Acute myocarditis may progress to dilated cardiomyopathy.
- Chronic active myocarditis: Chronic active myocarditis has a less distinct onset of the illness. There are clinical and histologic relapses and the development of ventricular dysfunction. Histologically, chronic inflammatory changes with mild to moderate fibrosis may be develop after 2 to 4 years.
- Chronic persistent myocarditis: Chronic persistent myocarditis has a less distinct onset of the illness. Histologically it is characterized by persistent infiltration and myocyte necrosis. Despite the presence of symptoms, ventricular dysfunction is absent.[14]
| Classification based on clinicopathological criteria | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fulminant myocarditis | Acute myocarditis | Chronic active myocarditis | Chronic persistent myocarditis | ||||||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ “Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies”. Circulation. 93 (5): 841–842. 1996. doi:10.1161/01.CIR.93.5.841. ISSN 0009-7322.
- ↑ 2.0 2.1 Leone, Ornella; Veinot, John P.; Angelini, Annalisa; Baandrup, Ulrik T.; Basso, Cristina; Berry, Gerald; Bruneval, Patrick; Burke, Margaret; Butany, Jagdish; Calabrese, Fiorella; d’Amati, Giulia; Edwards, William D.; Fallon, John T.; Fishbein, Michael C.; Gallagher, Patrick J.; Halushka, Marc K.; McManus, Bruce; Pucci, Angela; Rodriguez, E. René; Saffitz, Jeffrey E.; Sheppard, Mary N.; Steenbergen, Charles; Stone, James R.; Tan, Carmela; Thiene, Gaetano; van der Wal, Allard C.; Winters, Gayle L. (2012). “2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology”. Cardiovascular Pathology. 21 (4): 245–274. doi:10.1016/j.carpath.2011.10.001. ISSN 1054-8807.
- ↑ Kindermann, Ingrid; Barth, Christine; Mahfoud, Felix; Ukena, Christian; Lenski, Matthias; Yilmaz, Ali; Klingel, Karin; Kandolf, Reinhard; Sechtem, Udo; Cooper, Leslie T.; Böhm, Michael (2012). “Update on Myocarditis”. Journal of the American College of Cardiology. 59 (9): 779–792. doi:10.1016/j.jacc.2011.09.074. ISSN 0735-1097.
- ↑ Sagar, Sandeep; Liu, Peter P; Cooper, Leslie T (2012). “Myocarditis”. The Lancet. 379 (9817): 738–747. doi:10.1016/S0140-6736(11)60648-X. ISSN 0140-6736.
- ↑ Dennert, R.; Crijns, H. J.; Heymans, S. (2008). “Acute viral myocarditis”. European Heart Journal. 29 (17): 2073–2082. doi:10.1093/eurheartj/ehn296. ISSN 0195-668X.
- ↑ Maron, Barry J.; Towbin, Jeffrey A.; Thiene, Gaetano; Antzelevitch, Charles; Corrado, Domenico; Arnett, Donna; Moss, Arthur J.; Seidman, Christine E.; Young, James B. (2006). “Contemporary Definitions and Classification of the Cardiomyopathies”. Circulation. 113 (14): 1807–1816. doi:10.1161/CIRCULATIONAHA.106.174287. ISSN 0009-7322.
- ↑ Bock, Claus-Thomas; Klingel, Karin; Kandolf, Reinhard (2010). “Human Parvovirus B19–Associated Myocarditis”. New England Journal of Medicine. 362 (13): 1248–1249. doi:10.1056/NEJMc0911362. ISSN 0028-4793.
- ↑ P. Liu, T. Martino, M. A. Opavsky & J. Penninger (1996). “Viral myocarditis: balance between viral infection and immune response”. The Canadian journal of cardiology. 12 (10): 935–943. PMID 9191484. Unknown parameter
|month=ignored (help) - ↑ Cambridge, G; MacArthur, C G; Waterson, A P; Goodwin, J F; Oakley, C M (1979). “Antibodies to Coxsackie B viruses in congestive cardiomyopathy”. Heart. 41 (6): 692–696. doi:10.1136/hrt.41.6.692. ISSN 1355-6037.
- ↑ H. T. Aretz, M. E. Billingham, W. D. Edwards, S. M. Factor, J. T. Fallon, J. J. Jr Fenoglio, E. G. Olsen & F. J. Schoen (1987). “Myocarditis. A histopathologic definition and classification”. The American journal of cardiovascular pathology. 1 (1): 3–14. PMID 3455232. Unknown parameter
|month=ignored (help) - ↑ Gore, Ira; Saphir, Otto (1947). “Myocarditis”. American Heart Journal. 34 (6): 827–830. doi:10.1016/0002-8703(47)90147-6. ISSN 0002-8703.
- ↑ Felker, G.Michael; Boehmer, John P; Hruban, Ralph H; Hutchins, Grover M; Kasper, Edward K; Baughman, Kenneth L; Hare, Joshua M (2000). “Echocardiographic findings in fulminant and acute myocarditis”. Journal of the American College of Cardiology. 36 (1): 227–232. doi:10.1016/S0735-1097(00)00690-2. ISSN 0735-1097.
- ↑ Pinamonti, Bruno; Alberti, Ezip; Cigalotto, Alessandro; Dreas, Lorella; Salvi, Alessandro; Silvestri, Furio; Camerini, Fulvio (1988). “Echocardiographic findings in myocarditis”. The American Journal of Cardiology. 62 (4): 285–291. doi:10.1016/0002-9149(88)90226-3. ISSN 0002-9149.
- ↑ 14.0 14.1 Lieberman, Eric B.; Hutchins, Grover M.; Herskowitz, Ahvie; Rose, Noel R.; Baughman, Kenneth L. (1991). “Clinicopathoiogic description of myocarditis”. Journal of the American College of Cardiology. 18 (7): 1617–1626. doi:10.1016/0735-1097(91)90493-S. ISSN 0735-1097.
- ↑ Lieberman EB, Hutchins GM, Herskowitz A, Rose NR, Baughman KL (1991). “Clinicopathologic description of myocarditis”. J Am Coll Cardiol. 18 (7): 1617–26. PMID 1960305.
- ↑ McCarthy RE, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM; et al. (2000). “Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis”. N Engl J Med. 342 (10): 690–5. doi:10.1056/NEJM200003093421003. PMID 10706898.
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Varun Kumar, M.B.B.S., Maliha Shakil, M.D. [2] Homa Najafi, M.D.[3]
Overview
During either an infection or a hypersensitivity reaction, the inflammatory response may cause myonecrosis either directly or indirectly as part of an autoimmune reaction. Histopathological features include abundant edema in the myocardial interstitium and an inflammatory infiltrate which is rich in lymphocytes and macrophages. Focal destruction of myocytes as a result of the inflammatory process results in left ventricular dysfunction.
Pathogenesis
Myocarditis is a continuum of three phases of the disease processes with each one evolving into the next.[1]
Phase I: Viral Infection and Replication
Viruses such as coxsackie and enterovirus, get internalized in peripheral tissues and activate the immune system. A few of these viral genomes attach to the immunologic cells which circulate throughout the body and lodge in other organs such as the heart where they further replicate and cause localized tissue destruction.
Phase II: Autoimmune Injury
After the host immune system eliminates the viral genomes from the body, the immune system may remains activated in patients who develop myocarditis. This leads to the development of an autoimmune reaction where T-cells and cytokines target the host tissue such as the myocardium which causes further myocyte damage.
Phase III: Dilated Cardiomyopathy
- Cytokines, which are produced in reaction to infection and cell death, are a leading cause of dilated cardiomyopathy.
- Matrix metalloproteinases, such as gelatinase, collagenases, and elastases may also be activated by cytokines during the autoimmune phase.[2][3]
- Protease produced by coxsackie virus can modify the sarcoglycan complex in myocytes leading to ventricular dilation.[4]
Eosinophilic and hypersensitive myocarditis may occur secondary to parasitic infections, drug hypersensitivity or hypereosinophilic syndrome. Eosinophilic infiltration in myocardium lead to release of eosinophilic proteins which increase cellular membrane permeability which in turn leads to cell death.[5][6] The pathogenesis of this hypersensitivity reaction include either an immediate reaction which involves the degranulation of mast cells and basophils mediated by IgE, or a delayed reaction involving the activation of helper T-cells and interleukin-5.
Microscopic Pathology
Histopathological features include abundant edema in the myocardial interstitium and an inflammatory infiltrate which is rich in lymphocytes and macrophages. Focal destruction of myocytes as a result of the inflammatory process results in left ventricular dysfunction.[7]
The Heart in Toxoplasma gondii Myocarditis
{{#ev:youtube|2s9OuW9XlUw}}
The Heart in Coxsackie B2 Myocarditis
{{#ev:youtube|R_7AXF61QGg}}
References
- ↑ Liu PP, Mason JW (2001). “Advances in the understanding of myocarditis”. Circulation. 104 (9): 1076–82. PMID 11524405.
- ↑ Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S (1998). “Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling”. Circulation. 98 (2): 149–56. PMID 9679721.
- ↑ Lee JK, Zaidi SH, Liu P, Dawood F, Cheah AY, Wen WH; et al. (1998). “A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis”. Nat Med. 4 (12): 1383–91. doi:10.1038/3973. PMID 9846575.
- ↑ Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE; et al. (1999). “Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy”. Nat Med. 5 (3): 320–6. doi:10.1038/6543. PMID 10086389.
- ↑ Ginsberg F, Parrillo JE (2005). “Eosinophilic myocarditis”. Heart Fail Clin. 1 (3): 419–29. doi:10.1016/j.hfc.2005.06.013. PMID 17386864.
- ↑ Amini R, Nielsen C (2010). “Eosinophilic myocarditis mimicking acute coronary syndrome secondary to idiopathic hypereosinophilic syndrome: a case report”. J Med Case Reports. 4: 40. doi:10.1186/1752-1947-4-40. PMC 2830978. PMID 20181108.
- ↑ Feldman AM, McNamara D (2000). “Myocarditis”. N Engl J Med. 343 (19): 1388–98. doi:10.1056/NEJM200011093431908. PMID 11070105.
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Varun Kumar, M.B.B.S. Ogheneochuko Ajari, MB.BS, MS [2] Homa Najafi, M.D.[3]
Overview
Life-threatening causes of myocarditis include carbon monoxide poisoning and Dengue fever. Common causes of myocarditis include bacterial infections, Lyme disease, and medications. Idiopathic myocarditis is the most common type of myocarditis and is often suspected to be secondary to a viral infection.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.[1]
Common Causes
Causes by Organ System
Causes in Alphabetical Order
Overview
Disease name] may be caused by [cause1], [cause2], or [cause3].
OR
Common causes of [disease] include [cause1], [cause2], and [cause3].
OR
The most common cause of [disease name] is [cause 1]. Less common causes of [disease name] include [cause 2], [cause 3], and [cause 4].
OR
The cause of [disease name] has not been identified. To review risk factors for the development of [disease name], click here.
Causes
Life-threatening Causes
- Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. There are no life-threatening causes of disease name, however complications resulting from untreated disease name is common.
- Life-threatening causes of [symptom/manifestation] include [cause1], [cause2], and [cause3].
- [Cause] is a life-threatening cause of [disease].
Common Causes
Common causes of [disease name] may include:
- [Cause1]
- [Cause2]
- [Cause3]
OR
- [Disease name] is caused by an infection with [pathogen name].
- [Pathogen name] is caused by [pathogen name].
Less Common Causes
Less common causes of [disease name] include:
- [Cause1]
- [Cause2]
- [Cause3]
Genetic Causes
- [Disease name] is caused by a mutation in the [gene name] gene.
Causes of myocarditis:[22][23][24][25][26][27][28][29][30]
| Immune-mediated myocarditis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Allergens | Alloantigens | Autoantigens | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| -Tetanus toxoid
-Vaccines -Serum sickness | Drugs:
-Penicillin -Cefaclor -Colchicine -Furosemide -Isoniazid -Lidocaine -Tetracycline -Sulfonamides -Phenytoin -Phenylbutazone -Methyldopa -Thiazide diuretics -Amitriptyline | Heart transplant rejection | -Infection-negative lymphocytic
| Autoimmune disorders:
SLE, -Rheumatoid arthritis -Churg-Strauss syndrome -Kawasaki’s disease -IBD -Scleroderma -Polymyositis -Myasthenia gravis -DM type1 -Thyrotoxicosis -Sarcoidosis -Wegener’s granulomatosis -Rheumatic heart disease | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Toxic myocarditis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drugs | Heavy metals | Hormones | Physical agents | Miscellaneous | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| -Amphetamines
-Anthracyclines -Cocaine -Cyclophosphamide -Ethanol -Fluorouracil -Lithium -Catecholamines -Hematine -Interleukin-2 -Trastuzumab -Clozapine | -Copper
-Iron -Lead | -Phaeochromocytoma
| -Radiation
| -Scorpion sting
-Snake, and spider bites – Bee and wasp stings -Carbon monoxide -Inhalant -Phosphorus -Arsenic -Sodium azide | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Infectious myocarditis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Bacterial | Spirochaetal | Fungal | Protozoal | Parasitic | Rickettsial | Viral | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| -Staphylococcus
-Streptococcus -Pneumococcus -Meningococcus -Gonococcus -Salmonella -Corynebacterium diphtheriae -Haemophilus influenzae -Mycobacterium tuberculosis -Mycoplasma pneumonia -Brucella | -Borrelia -Leptospira | – Aspergillus
-Actinomyces -Blastomyces -Candida -Coccidioides -Cryptococcus -Histoplasma -Mucormycosis -Nocardia -Sporothrix | -Trypanosoma cruzi
-Toxoplasma gondii -Entamoeba -Leishmania | -Trichinella spiralis
-Echinococcus granulosus -Taenia solium | -Coxiella burnetii
-R.rickettsii -R.tsutsugamushi | -Coxsackievirus
-Echoviruses -Polioviruses -Influenza A & B viruses -RSV -Mumps virus -Measles virus -Rubella virus -Hepatitis C virus -Dengue virus -Yellow fever virus -HIV-1 -Adenoviruses -Paravirus B19 -Cytomegalovirus -HSV-6 -EBV -VZV -HSV | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ Marques N, Gan VC, Leo YS (2013). “Dengue myocarditis in Singapore: two case reports”. Infection. 41 (3): 709–14. doi:10.1007/s15010-012-0392-9. PMID 23277366. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Centers for Disease Control and Prevention (CDC) (2013). “Three sudden cardiac deaths associated with Lyme carditis – United States, November 2012-July 2013”. MMWR Morb Mortal Wkly Rep. 62 (49): 993–6. PMID 24336130. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ 3.0 3.1 3.2 3.3 Bowles NE, Ni J, Kearney DL, Pauschinger M, Schultheiss HP, McCarthy R; et al. (2003). “Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults”. J Am Coll Cardiol. 42 (3): 466–72. PMID 12906974. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W; et al. (2005). “Viral persistence in the myocardium is associated with progressive cardiac dysfunction”. Circulation. 112 (13): 1965–70. doi:10.1161/CIRCULATIONAHA.105.548156. PMID 16172268. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ 5.0 5.1 Roghi A, Pedrotti P, Milazzo A, Bonacina E, Bucciarelli-Ducci C (2011). “Adrenergic myocarditis in pheochromocytoma”. J Cardiovasc Magn Reson. 13: 4. doi:10.1186/1532-429X-13-4. PMC 3025878. PMID 21223554. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Pursnani A, Yee H, Slater W, Sarswat N (2009). “Hypersensitivity myocarditis associated with azithromycin exposure”. Ann Intern Med. 150 (3): 225–6. PMID 19189924. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Frustaci A, Cuoco L, Chimenti C, Pieroni M, Fioravanti G, Gentiloni N; et al. (2002). “Celiac disease associated with autoimmune myocarditis”. Circulation. 105 (22): 2611–8. PMID 12045166.
- ↑ Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L; et al. (2007). “Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003”. Drug Saf. 30 (1): 47–57. PMID 17194170. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Rose NR, Neumann DA, Herskowitz A (1992). “Coxsackievirus myocarditis”. Adv Intern Med. 37: 411–29. PMID 1558005.
- ↑ Grist NR, Bell EJ (1969). “Coxsackie viruses and the heart”. Am Heart J. 77 (3): 295–300. PMID 4887187.
- ↑ Cohen JI, Corey GR (1985). “Cytomegalovirus infection in the normal host”. Medicine (Baltimore). 64 (2): 100–14. PMID 2983175.
- ↑ Spear GS (1995). “Eosinophilic explant carditis with eosinophilia: ?Hypersensitivity to dobutamine infusion”. J Heart Lung Transplant. 14 (4): 755–60. PMID 7578186.
- ↑ Johnson MR (2004). “Eosinophilic myocarditis in the explanted hearts of cardiac transplant recipients: Interesting pathologic finding or pathophysiologic entity of clinical significance?”. Crit Care Med. 32 (3): 888–90. PMID 15090985. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Taliercio CP, Olney BA, Lie JT (1985). “Myocarditis related to drug hypersensitivity”. Mayo Clin Proc. 60 (7): 463–8. PMID 4010343.
- ↑ Ben m’rad M, Leclerc-Mercier S, Blanche P, Franck N, Rozenberg F, Fulla Y; et al. (2009). “Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients”. Medicine (Baltimore). 88 (3): 131–40. doi:10.1097/MD.0b013e3181a4d1a1. PMID 19440116. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Chimenti C, Russo A, Pieroni M, Calabrese F, Verardo R, Thiene G; et al. (2004). “Intramyocyte detection of Epstein-Barr virus genome by laser capture microdissection in patients with inflammatory cardiomyopathy”. Circulation. 110 (23): 3534–9. doi:10.1161/01.CIR.0000148823.08092.0E. PMID 15557377. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Cooper LT, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC; et al. (2008). “Usefulness of immunosuppression for giant cell myocarditis”. Am J Cardiol. 102 (11): 1535–9. doi:10.1016/j.amjcard.2008.07.041. PMC 2613862. PMID 19026310. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Matsumori A, Yutani C, Ikeda Y, Kawai S, Sasayama S (2000). “Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy”. Lab Invest. 80 (7): 1137–42. PMID 10908160.
- ↑ Breinholt JP, Moulik M, Dreyer WJ, Denfield SW, Kim JJ, Jefferies JL; et al. (2010). “Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients”. J Heart Lung Transplant. 29 (7): 739–46. doi:10.1016/j.healun.2010.03.003. PMC 2902647. PMID 20456978. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B (2003). “Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens”. Hum Pathol. 34 (5): 497–503. PMID 12792925. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Cassimatis DC, Atwood JE, Engler RM, Linz PE, Grabenstein JD, Vernalis MN (2004). “Smallpox vaccination and myopericarditis: a clinical review”. J Am Coll Cardiol. 43 (9): 1503–10. doi:10.1016/j.jacc.2003.11.053. PMID 15120802. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ “Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies”. Circulation. 93 (5): 841–842. 1996. doi:10.1161/01.CIR.93.5.841. ISSN 0009-7322.
- ↑ Leone, Ornella; Veinot, John P.; Angelini, Annalisa; Baandrup, Ulrik T.; Basso, Cristina; Berry, Gerald; Bruneval, Patrick; Burke, Margaret; Butany, Jagdish; Calabrese, Fiorella; d’Amati, Giulia; Edwards, William D.; Fallon, John T.; Fishbein, Michael C.; Gallagher, Patrick J.; Halushka, Marc K.; McManus, Bruce; Pucci, Angela; Rodriguez, E. René; Saffitz, Jeffrey E.; Sheppard, Mary N.; Steenbergen, Charles; Stone, James R.; Tan, Carmela; Thiene, Gaetano; van der Wal, Allard C.; Winters, Gayle L. (2012). “2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology”. Cardiovascular Pathology. 21 (4): 245–274. doi:10.1016/j.carpath.2011.10.001. ISSN 1054-8807.
- ↑ Kindermann, Ingrid; Barth, Christine; Mahfoud, Felix; Ukena, Christian; Lenski, Matthias; Yilmaz, Ali; Klingel, Karin; Kandolf, Reinhard; Sechtem, Udo; Cooper, Leslie T.; Böhm, Michael (2012). “Update on Myocarditis”. Journal of the American College of Cardiology. 59 (9): 779–792. doi:10.1016/j.jacc.2011.09.074. ISSN 0735-1097.
- ↑ Sagar, Sandeep; Liu, Peter P; Cooper, Leslie T (2012). “Myocarditis”. The Lancet. 379 (9817): 738–747. doi:10.1016/S0140-6736(11)60648-X. ISSN 0140-6736.
- ↑ Dennert, R.; Crijns, H. J.; Heymans, S. (2008). “Acute viral myocarditis”. European Heart Journal. 29 (17): 2073–2082. doi:10.1093/eurheartj/ehn296. ISSN 0195-668X.
- ↑ Maron, Barry J.; Towbin, Jeffrey A.; Thiene, Gaetano; Antzelevitch, Charles; Corrado, Domenico; Arnett, Donna; Moss, Arthur J.; Seidman, Christine E.; Young, James B. (2006). “Contemporary Definitions and Classification of the Cardiomyopathies”. Circulation. 113 (14): 1807–1816. doi:10.1161/CIRCULATIONAHA.106.174287. ISSN 0009-7322.
- ↑ Bock, Claus-Thomas; Klingel, Karin; Kandolf, Reinhard (2010). “Human Parvovirus B19–Associated Myocarditis”. New England Journal of Medicine. 362 (13): 1248–1249. doi:10.1056/NEJMc0911362. ISSN 0028-4793.
- ↑ P. Liu, T. Martino, M. A. Opavsky & J. Penninger (1996). “Viral myocarditis: balance between viral infection and immune response”. The Canadian journal of cardiology. 12 (10): 935–943. PMID 9191484. Unknown parameter
|month=ignored (help) - ↑ Cambridge, G; MacArthur, C G; Waterson, A P; Goodwin, J F; Oakley, C M (1979). “Antibodies to Coxsackie B viruses in congestive cardiomyopathy”. Heart. 41 (6): 692–696. doi:10.1136/hrt.41.6.692. ISSN 1355-6037.
Differentiating Myocarditis from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maliha Shakil, M.D. [2] Homa Najafi, M.D.[3]
Overview
Myocarditis must be differentiated from other causes of chest pain such as ST elevation myocardial infarction, pericarditis, and unstable angina. Myocarditis must also be differentiated from pulmonary edema and alcoholic cardiomyopathy.
Differential Diagnosis
| Differential Diagnosis | History and Symptoms | Physical Examination | Laboratory Findings | Imaging Findings |
|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Differentiating Myocarditis from ST Segment Elevation Myocardial Infarction
Both diseases present with chest pain, elevated cardiac biomarkers, and focal left ventricular dysfunction. There are two studies that can be used to distinguish the two syndromes:
Coronary Angiography
Coronary angiography can be performed to distinguish myocarditis from ST segment elevation myocardial infarction. ST segment elevation myocardial infarction is associated with either complete or subtotal occlusion of an epicardial coronary artery on coronary angiography. When used in conjunction with the findings on coronary angiography, cardiac MRI is useful in establishing the diagnosis of myocarditis.[1]
Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging is also useful in distinguishing between the two diseases as well. On cardiac MRI, myocarditis is associated with patchy, non-sentimental, hyperenhancement which is confined to the epicardial layer of the myocardium. In contrast, in ST segment elevation myocardial infarction there is confluent hyperenhancement extending from the endocardium in a distribution that mimics the distribution of the epicardial coronary arteries.
Differentiating Myocarditis from Pericarditis
Both diseases present with chest pain and ST segment elevation. The two conditions can be distinguished by the following studies:
Electrocardiogram
While both disorders are associated with ST segment elevation, pericarditis is also associated with PR segment depression.
Cardiac Biomarkers
Myocarditis is associated with elevations of the CK-MB and the troponin, while pericarditis is not. If pericarditis is associated with underlying inflammation of the myocardium, then this is called myopericarditis. If there is concomitant involvement of both the pericardium and myocardium in myopericarditis, then there are elevations of the cardiac biomarkers.
Echocardiography
In patients with myocarditis there will be a focal wall motion abnormalities, while these will be absent in patients with pericarditis. There may be a pericardial effusion in the patient with pericarditis, while myocarditis is not associated with a pericardial effusion.
Overview
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
References
- ↑ Monney PA, Sekhri N, Burchell T, Knight C, Davies C, Deaner A; et al. (2011). “Acute myocarditis presenting as acute coronary syndrome: role of early cardiac magnetic resonance in its diagnosis”. Heart. 97 (16): 1312–8. doi:10.1136/hrt.2010.204818. PMID 21106555. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help)
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor-In-Chief: Varun Kumar, M.B.B.S., Cafer Zorkun, M.D., Ph.D. [2], Maliha Shakil, M.D. [3]
Overview
In young adults, up to 20% of all cases of sudden death are due to myocarditis. Myocarditis is slightly more frequent among males than females.[1]
Epidemiology and Demographics
Prevalence
In routine autopsies, 1-9% of all patients had evidence of myocardial inflammation.
Age
In young adults, up to 20% of all cases of sudden death are due to myocarditis.
Gender
Myocarditis is slightly more frequent among males than females. This may be due to protection conferred by the ovarian cycle.[1]
Race
No difference in frequency of myocarditis has been observed between various races.
Etiology in Developed Countries
- Viral infections are the most common cause of myocarditis in developed countries.
- Common viral causes include coxsackie B and enterovirus.
- The frequency of dilated cardiomyopathy secondary to myocarditis is 7.5-10 per 100,000 individuals with enterovirus infections, with the Coxsackie-B viruses being the most common cause.[2]
- Recent studies show that adenovirus, parvovirus B19, hepatitis C, and human herpes virus 6 were the common causes for myocarditis.[3][4]
- Myocarditis secondary to lyme disease should be suspected in people traveling to regions where it is endemic, particularly if there are associated conduction abnormalities of the heart.[5]
Etiology in Developing Countries
In South America, Chagas’ disease (caused by Trypanosoma cruzi) is the main cause of myocarditis. Other causes in developing countries include rheumatic fever[6] and HIV infection.
References
- ↑ 1.0 1.1 Schwartz J, Sartini D, Huber S (2004). “Myocarditis susceptibility in female mice depends upon ovarian cycle phase at infection”. Virology. 330 (1): 16–23. doi:10.1016/j.virol.2004.06.051. PMID 15527830.
- ↑ Friman G, Wesslén L, Fohlman J, Karjalainen J, Rolf C (1995). “The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy”. Eur Heart J. 16 Suppl O: 36–41. PMID 8682098.
- ↑ Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T; et al. (2008). “Predictors of outcome in patients with suspected myocarditis”. Circulation. 118 (6): 639–48. doi:10.1161/CIRCULATIONAHA.108.769489. PMID 18645053. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D; et al. (2005). “High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction”. Circulation. 111 (7): 887–93. doi:10.1161/01.CIR.0000155616.07901.35. PMID 15699250. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ McAlister HF, Klementowicz PT, Andrews C, Fisher JD, Feld M, Furman S (1989). “Lyme carditis: an important cause of reversible heart block”. Ann Intern Med. 110 (5): 339–45. PMID 2644885.
- ↑ Carapetis JR, Steer AC, Mulholland EK, Weber M (2005). “The global burden of group A streptococcal diseases”. Lancet Infect Dis. 5 (11): 685–94. doi:10.1016/S1473-3099(05)70267-X. PMID 16253886.
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Varun Kumar M.B.B.S., Maliha Shakil, M.D. [2] Homa Najafi, M.D.[3]
Overview
Myocarditis is usually self limiting and is associated with a good prognosis especially if it is secondary to a viral infection. Patients rarely develop cardiac failure, pulmonary edema, arrhythmias, or cardiogenic shock. In some instances, myocarditis may be associated with sudden death. Patients with fulminant myocarditis have a good long term prognosis if they survive the acute phase of the disease. The prognosis of fulminant myocarditis is better than that of either acute myocarditis or giant cell myocarditis. The presence of syncope, pulmonary hypertension, biventricular dysfunction, left bundle branch block, q waves, AV block, and a left ventricular ejection fraction < 40% are associated with sudden death and cardiac transplantation. Complications of myocarditis include chronic dilated cardiomyopathy, heart block, congestive heart failure, pericarditis, ventricular dysfunction, arrythmias, and sudden cardiac death.
Natural History
- The course of viral myocarditis is usually benign and the majority of cases of Coxsackie B virus infection are subclinical.
- Patients presenting with mild ventricular dysfunction secondary to viral myocarditis typically improve within weeks to months and rarely progress to severe ventricular dysfunction, heart block, arrhythmias, or even sudden cardiac death.
- Among patients who present with more advanced left ventricular dysfunction; 50% of patients develop chronic ventricular dysfunction and 25% have spontaneous improvement in ventricular function while the remaining 25% progress to transplantation or death.[1][2][3]
Complications
- Complications of myocarditis include:[1][2][3]
Prognosis
Endomyocardial Biopsy
- An endomyocardial biopsy is usually obtained in patients presenting with advanced heart failure or arrhythmias. The endomyocardial biopsy can shed light on the prognosis by ascertaining the underlying cause and the histopathologic severity of the disease.
- The markers which can be associated with poor prognosis include:[4][5][6][7][8][9]
- Fas and Fas ligand (cell death receptors) are associated with apoptotic death of myocytes and are a marker of cardiac dysfunction.
- Antimyosin autoantibodies are associated with left ventricular systolic dysfunction and diastolic stiffness in patients with chronic myocarditis.
- Persistence of the viral genome in the myocardium is associated with worsening of left ventricular ejection fraction.
- Giant cell myocarditis (GCM) is a less common form of myocarditis which usually occurs in relatively young and healthy adults. It is associated with a poorer prognosis.
- High levels of interleukin-10 in fulminant myocarditis patients at admission may be predictive of subsequent development of cardiogenic shock (requiring mechanical cardiopulmonary support system) and mortality.
Prognostic Implications of EKG Changes
- Despite its worrisome appearance, ST segment elevation suggestive of myocardial infarction is usually self-limited with no overt sequelae.[10][11]
- In contrast, the presence of either left bundle branch block, q waves suggestive of old infarct or high degree AV block is associated with a poor long term prognosis, development of cardiac failure and the need for cardiac transplantation.
Clinical Predictors of Prognosis
- The clinical manifestations which can associated with poor prognosis (associated with death or cardiac transplantation) include: [12][13]
Prognosis Associated with Left Ventricular Dysfunction
- The prognosis in patients with new onset heart failure depends on the degree of ventricular dysfunction.[1][14]
- The majority of myocarditis patients recover well with treatment. However, approximately 25% of patients develop chronic ventricular dysfunction and 25% of patients will continue to deteriorate.
Prognosis Associated with Fulminant Myocarditis vs Acute Myocarditis
- In a small series of 15 patients with fulminant myocarditis, 14(93%) survived for 11 years without the need for cardiac transplantation. This suggests that patients with fulminant myocarditis have a good long term prognosis if they survive the acute phase of the disease. In the same series, 132 patients met the criteria for acute myocarditis and 60(45%) of these patients were alive at the end of 11 years without having received a cardiac transplant.[15]
References
- ↑ 1.0 1.1 1.2 Magnani JW, Dec GW (2006). “Myocarditis: current trends in diagnosis and treatment”. Circulation. 113 (6): 876–90. doi:10.1161/CIRCULATIONAHA.105.584532. PMID 16476862.
- ↑ 2.0 2.1 Wentworth P, Jentz LA, Croal AE (1979). “Analysis of sudden unexpected death in southern Ontario, with emphasis on myocarditis”. Can Med Assoc J. 120 (6): 676–80, 706. PMC 1819176. PMID 436050.
- ↑ 3.0 3.1 Hosenpud JD, McAnulty JH, Niles NR (1986). “Unexpected myocardial disease in patients with life threatening arrhythmias”. Br Heart J. 56 (1): 55–61. PMC 1277385. PMID 3730208.
- ↑ Sheppard R, Bedi M, Kubota T, Semigran MJ, Dec W, Holubkov R; et al. (2005). “Myocardial expression of fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy”. J Am Coll Cardiol. 46 (6): 1036–42. doi:10.1016/j.jacc.2005.05.067. PMID 16168288. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Lauer B, Schannwell M, Kühl U, Strauer BE, Schultheiss HP (2000). “Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis”. J Am Coll Cardiol. 35 (1): 11–8. PMID 10636253. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W; et al. (2005). “Viral persistence in the myocardium is associated with progressive cardiac dysfunction”. Circulation. 112 (13): 1965–70. doi:10.1161/CIRCULATIONAHA.105.548156. PMID 16172268. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Cooper LT (2009). “Myocarditis”. N Engl J Med. 360 (15): 1526–38. doi:10.1056/NEJMra0800028. PMID 19357408. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Cooper LT, Berry GJ, Shabetai R (1997). “Idiopathic giant-cell myocarditis–natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators”. N Engl J Med. 336 (26): 1860–6. doi:10.1056/NEJM199706263362603. PMID 9197214.
- ↑ Nishii M, Inomata T, Takehana H, Takeuchi I, Nakano H, Koitabashi T; et al. (2004). “Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis”. J Am Coll Cardiol. 44 (6): 1292–7. doi:10.1016/j.jacc.2004.01.055. PMID 15364334. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Dec GW, Waldman H, Southern J, Fallon JT, Hutter AM, Palacios I (1992). “Viral myocarditis mimicking acute myocardial infarction”. J Am Coll Cardiol. 20 (1): 85–9. PMID 1607543. Unknown parameter
|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=ignored (help) - ↑ Nakashima H, Katayama T, Ishizaki M, Takeno M, Honda Y, Yano K (1998). “Q wave and non-Q wave myocarditis with special reference to clinical significance”. Jpn Heart J. 39 (6): 763–74. PMID 10089938.
- ↑ Alida L. P. Caforio, Fiorella Calabrese, Annalisa Angelini, Francesco Tona, Annalisa Vinci, Stefania Bottaro, Angelo Ramondo, Elisa Carturan, Sabino Iliceto, Gaetano Thiene & Luciano Daliento (2007). “A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis”. European heart journal. 28 (11): 1326–1333. doi:10.1093/eurheartj/ehm076. PMID 17493945. Unknown parameter
|month=ignored (help) - ↑ Thomas P. Cappola, G. Michael Felker, W. H. Linda Kao, Joshua M. Hare, Kenneth L. Baughman & Edward K. Kasper (2002). “Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk”. Circulation. 105 (14): 1663–1668. doi:10.1161/01.cir.0000013771.30198.82. PMID 11940544. Unknown parameter
|month=ignored (help) - ↑ Magnani JW, Danik HJ, Dec GW, DiSalvo TG (2006). “Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors”. Am Heart J. 151 (2): 463–70. doi:10.1016/j.ahj.2005.03.037. PMID 16442915.
- ↑ McCarthy RE, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM; et al. (2000). “Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis”. N Engl J Med. 342 (10): 690–5. doi:10.1056/NEJM200003093421003. PMID 10706898.
Diagnosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Endomyocardial Biopsy | Chest X Ray | MRI | Echocardiography | Other Imaging Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
